Paper 58 - IDENTIFICATION OF UBIQUITIN PROTEASOME COMPONENTS REGULATING THE STABILITY OF FUSION ONCOPROTEINS IN SARCOMA

Co-Author(s)

• KB

  Kilian Bales

  MD thesis student
  Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• LC

  Liang Chen, M.Sc.

  Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• DK

  Dawid Krzeciesa, Ph.D.

  West German Cancer Center, University Hospital Essen
  Essen, Nordrhein-Westfalen, Germany
• AR

  Adarsh Raveendran, M.Sc.

  Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• NB

  Nicola Biondi, n/a

  Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• KL

  Kwang Seok Lee, Ph.D.

  Division of Translational Medical Oncology, DKFZ and NCT Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• SF

  Stefan Fröhling, M.D.

  Division of Translational Medical Oncology, DKFZ and NCT Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• CS

  Claudia Scholl, M.D.

  Division of Applied Functional Genomics, DKFZ and NCT Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany
• DS

  David Shorthouse, Ph.D.

  University College London, UCL School of Pharmacy
  London, England, United Kingdom
• NP

  Nischalan Pillay, M.D.

  University College London, UCL Cancer Institute
  London, England, United Kingdom
• RS

  Rob Sellar, M.D.

  University College London, UCL Cancer Institute
  London, England, United Kingdom
• SB

  Sebastian Bauer, MD (he/him/his)

  Director
  Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen
  Essen, Nordrhein-Westfalen, Germany
• MS

  Mikołaj Słabicki, Ph.D.

  Broad Institute of MIT and Harvard, Cambridge and Department of Medical Oncology, Dana-Farber Cancer Institute
  Boston, Massachusetts, United States

Author(s)

• 

  Priya Chudasama, PhD

  Research Group Leader
  German Cancer Research Center
  Heidelberg, Baden-Wurttemberg, Germany